Publications by authors named "Lucas Victoria de Oliveira Martins"
Article Synopsis
- Systemic sclerosis (SSc) is a complex autoimmune disease, and recent clinical trials have prompted an update to the treatment guidelines from the Brazilian Society of Rheumatology.
- A systematic review was conducted using randomized clinical trials, following the PICO framework, with evidence graded by GRADE methodology to create new treatment recommendations.
- Six specific pharmacological recommendations were formulated, including new drugs like rituximab and nintedanib for managing various SSc-related complications, including skin issues and interstitial lung disease.
Joint involvement, including arthralgia, inflammatory arthritis, joint contractures and overlapping with rheumatoid arthritis, is a common manifestation and is associated with impared quality of life in systemic sclerosis (SSc). Few studies have evaluated the treatment of arthritis in SSc. Pharmacological approach includes low-dose corticosteroids, methotrexate, and hydroxychloroquine.
View Article and Find Full Text PDFIntroduction: COVID-19 may be associated with greater severity and mortality in patients with systemic sclerosis (SSc). The present study aimed to evaluate the prevalence, severity and mortality of COVID-19 in a Brazilian cohort of SSc patients.
Methods: This multicenter, retrospective, observational study included 1,042 SSc patients followed in four centers of São Paulo between March 2020 and June 2021.
Objectives: The aim of this study was to identify risk factors associated with mortality in patients with systemic sclerosis (SSc), particularly those with interstitial lung disease (ILD), over a long-term follow-up in a large Brazilian SSc cohort.
Methods: We conducted a medical records review study of 380 scleroderma patients from 1982 to 2019. Systemic sclerosis ILD was considered in those with evidence of ILD on chest high-resolution computed tomography (HRCT).